CD79B and non-Hodgkin lymphoma: The selection and screening of research articles related to the study aim “Efficacy of polatuzumab vedotin as CD79B gene targeting drug for treatment of Non-Hodgkin Lymphoma patients” was performed according to the PRISMA guidelines in this systematic review and meta-analysis.